Janssen, High Wycombe – 18th August 2016 – Janssen is disappointed with the draft Appraisal Consultation Document (ACD) published today by the National Institute for Health and Care Excellence (NICE), which states that it does not recommend ibrutinib for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL).[i] MCL is a chronic and incurable disease and patients have approximately 27% chance of surviving five years after diagnosis.[ii] Around 500 patients are diagnosed with MCL each year in the UK, with the majority over 60 years of age. [iii]
Jennifer Lee, Director of Health Economics, Market Access & Reimbursement at Janssen UK, said: “Ibrutinib is the most requested treatment on the Cancer Drugs Fund (CDF) for patients with this hard-to-treat cancer. Janssen remains committed to continuing to work with both NICE and NHS England, to ensure that permanent access to ibrutinib is achieved for patients with relapsed or refractory MCL through a positive NICE recommendation.”
Ibrutinib was recently recommended by the Scottish Medicines Consortium (SMC) in Scotland for relapsed or refractory MCL, and Janssen is aiming to achieve the same outcome in England and Wales. Janssen is continuing to work with NHS England and NICE through the CDF transition towards a positive solution, so that all patients who could benefit from ibrutinib can receive it in the future.Editor's Details
Last updated on: 23/08/2016
PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.